Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
International Journal of Molecular Sciences · 27.07.2023 · 24 (15) · 12030
DOI: 10.3390/ijms241512030 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.07.2023. Verfasst von Fernand Bteich und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Montefiore Medical Center, Bronx, NY 10467, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, US National Institute of Health, Price Family Foundation.
Abstract (Originalsprache)
Colorectal cancer (CRC) is a heterogeneous disease with a myriad of alterations at the cellular and molecular levels. Kristen rat sarcoma (KRAS) mutations occur in up to 40% of CRCs and serve as both a prognostic and predictive biomarker. Oncogenic mutations in the KRAS protein affect cellular proliferation and survival, leading to tumorigenesis through RAS/MAPK pathways. Until recently, only indirect targeting of the pathway had been investigated. There are now several KRAS allele-specific inhibitors in late-phase clinical trials, and many newer agents and targeting strategies undergoing preclinical and early-phase clinical testing. The adequate treatment of KRAS-mutated CRC will inevitably involve combination therapies due to the existence of robust adaptive resistance mechanisms in these tumors. In this article, we review the most recent understanding and findings related to targeting KRAS mutations in CRC, mechanisms of resistance to KRAS inhibitors, as well as evolving treatment strategies for KRAS-mutated CRC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Montefiore Medical Center, Bronx, NY 10467, USA.
- Department of Medical Oncology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
- Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
- Oncology Unit, Third Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, National and Kapodistrian University of Athens, 11527 Athens, Greece.
ORCID-Profile: Amalia Sofianidi, Ning Wei, Chaoyuan Kuang
Förderung
- NCI NIH HHS
- US National Institute of Health
- Price Family Foundation
Zitieren
APA
Bteich, F., Mohammadi, M., Li, T., Bhat, M. A., Sofianidi, A., Wei, N., & Kuang, C. (2023). Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review. International Journal of Molecular Sciences, 24(15), 12030. https://doi.org/10.3390/ijms241512030
Vancouver
Bteich F, Mohammadi M, Li T, Bhat MA, Sofianidi A, Wei N, et al. Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review. International Journal of Molecular Sciences. 2023;24(15):12030. doi:10.3390/ijms241512030
BibTeX
@article{Bteich2023,
author = {Bteich, Fernand and Mohammadi, Mahshid and Li, Terence and Bhat, Muzaffer Ahmed and Sofianidi, Amalia and Wei, Ning and Kuang, Chaoyuan},
title = {Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {15},
pages = {12030},
doi = {10.3390/ijms241512030}
}
EUVIMED